大家健康（中旬版）
大傢健康（中旬版）
대가건강（중순판）
GOOD HEALTH FOR ALL
2015年
4期
8-8
,共1页
未经保护的制备吉非替尼的起始化合物6－羟基－7－甲氧基－3，4－二氢喹唑啉－4－酮与少于两倍量的3－吗啉代丙基氯反应时生成4－或6－位单取代的化合物，当与大于两倍量的3－吗啉代丙基氯反应时生成4－和6－位双取代的化合物。
未經保護的製備吉非替尼的起始化閤物6－羥基－7－甲氧基－3，4－二氫喹唑啉－4－酮與少于兩倍量的3－嗎啉代丙基氯反應時生成4－或6－位單取代的化閤物，噹與大于兩倍量的3－嗎啉代丙基氯反應時生成4－和6－位雙取代的化閤物。
미경보호적제비길비체니적기시화합물6－간기－7－갑양기－3，4－이경규서람－4－동여소우량배량적3－마람대병기록반응시생성4－혹6－위단취대적화합물，당여대우량배량적3－마람대병기록반응시생성4－화6－위쌍취대적화합물。
When the un-protected starting compound 6-hydroxy-7 -methoxy-3,4 -dihydro-quinazoline-4 -one in order to prepare ge-fitinib reacts with less than 2 times'amount of 3 -morpholino-propyl chloride,the 4 - or 6 - position's mono substituted compound is produced. When the un-protected starting compound 6-hydroxy-7-methoxy-3,4-dihydro-quinazoline-4-one in order to prepare gefitinib reacts with more than 2 times'amount of 3-morpholino-propyl chloride,the 4- and 6- position's bis substituted compound is produced.
